Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05227690 · ClinicalTrials.gov registry record · Phase 2
A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
A Phase 2 study of Schizophrenia, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 385
- Enrollment target
- 20
- Study locations
NCT05227690: Completed Phase 2 study of Schizophrenia, sponsored by AbbVie.
NCT05227690 is a Phase 2 study of Schizophrenia that has completed, run by AbbVie. The registered enrollment target is 385 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (77% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05227690, a Phase 2 study of Schizophrenia, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 385 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (10 mg QD and 30 mg QD) in male and female participants who have schizophrenia and are experiencing an acute exacerbation of psychosis.
Primary Outcome
The PANSS measures symptom severity of participants with schizophrenia and contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale with a total minimum score of 30 and a maximum score of 210. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Emraclidine 10 mg
- DRUG Emraclidine 30 mg
Study Locations (20)
California
- Anaheim, California - Anaheim
- Garden Grove, California - Garden Grove
- Lemon Grove, California - Lemon Grove
- Montclair, California - Montclair
- Riverside, California - Riverside
- San Diego, California - San Diego
Florida
- Hialeah, Florida - Hialeah
- Hollywood, Florida - Hollywood
- Mangonia Park, Florida - Mangonia Park
- Oakland Park, Florida - Oakland Park
Texas
- DeSoto, Texas - DeSoto
- Houston, Texas - Houston
- Irving, Texas - Irving
Georgia
- Atlanta, Georgia - Atlanta
- Decatur, Georgia - Decatur
Arkansas
- Little Rock, Arkansas - Little Rock
Louisiana
- Shreveport, Louisiana - Shreveport
Maryland
- Gaithersburg, Maryland - Gaithersburg
Mississippi
- Flowood, Mississippi - Flowood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 385 participants |
| Start Date | 2022-06-30 |
| Est. Completion | 2024-08-26 |
| Phase | Phase 2 |
What the finished NCT05227690 record still lists
NCT05227690 is an interventional study that assigns participants to a tested intervention. The registered 385 participants enrollment target is mid-sized for trials with a published cap, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (77% higher).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05227690 names 20 study sites across 9 states, led by California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT05227690 about?
NCT05227690 is a clinical study titled "A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia". This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (10 mg QD and 30 mg QD) in male and female participants who have schizophrenia and are experiencing ...
What is the current status of trial NCT05227690?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 385 participants. The study started on 2022-06-30. Estimated completion is 2024-08-26.
What conditions does trial NCT05227690 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT05227690?
The interventions under investigation include: Placebo (DRUG), Emraclidine 10 mg (DRUG), Emraclidine 30 mg (DRUG).
Who is sponsoring clinical trial NCT05227690?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05227690 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05227690's enrollment target sits among peer trials
385 47th of 315 higher than 269 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
RECRUITING · Phase 2
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
RECRUITING · Phase 2
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
RECRUITING · Phase 2
-
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05373823 · 385 participants · NA
MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
- NCT05503173 · 385 participants · NA
Telehealth for Pain and Unhealthy Drinking Among PLWH
- NCT06226883 · 385 participants · Phase 2
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- NCT06290063 · 385 participants · Phase 2
Cannabidiol and Older Adult Cannabis Users
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI